47 results on '"Villamor N"'
Search Results
2. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact
3. Recurrent mutations refine prognosis in chronic lymphocytic leukemia
4. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells
5. Comparison of four prognostic scores in peripheral T-cell lymphoma
6. Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size
7. TESTICULAR LARGE B‐CELL LYMPHOMA IS GENETICALLY SIMILAR TO PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA AND DISTINCT FROM NODAL DIFFUSE LARGE B‐CELL LYMPHOMA.
8. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
9. Improving efficiency and sensitivity: European Research Initiative in CLL (ERIC) update on the international harmonised approach for flow cytometric residual disease monitoring in CLL
10. Central nervous system involvement in mantle cell lymphoma
11. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells
12. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
13. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]
14. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells
15. Acute myeloid leukemia with MLL rearrangements: clinicobiological features, prognostic impact and value of flow cytometry in the detection of residual leukemic cells
16. Frequent somatic mutations in components of the RNA processing machinery in chronic lymphocytic leukemia
17. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?
18. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma
19. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
20. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells
21. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias
22. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase
23. Acute myeloblastic leukemia with minimal myeloid differentiation: phenotypical and ultrastructural characteristics
24. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients
25. Granular lymphocyte proliferative disorders: A multicenter study of 20 cases
26. Treatment of early stage-B chronic lymphocytic leukemia with alpha-2b interferon after chlorambucil reduction of the tumoral mass
27. Identification of a natural soluble form of human CD5
28. Immunophenotypic and ultrastructural study in peripheral blood neutrophil granulocytes following bone marrow transplantation
29. IMMUNE PROFILE IN THE PERIPHERAL BLOOD (PB) OF PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AT DIAGNOSIS AND UPON RELAPSE.
30. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL.
31. PB2088: IMMUNE PROFILE OF PATIENTS WITH FOLLICULAR LYMPHOMA ASSESSED BY FLOW CYTOMETRY IN PERIPHERAL BLOOD: CHARACTERISTICS AT DIAGNOSIS AND AT RELAPSE OF THE DISEASE.
32. P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B‐CELL LYMPHOMA.
33. PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE.
34. Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia.
35. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.
36. A variant of Glanzmann's thrombasthenia which fails to express a GPIIb-IIIa related epitope that is recognized by a specific monoclonal antibody (C17).
37. Ristocetin induces platelet aggregation: a morphological demonstration.
38. GENOTYPING PRIMARY MEDIASTINAL B‐CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS.
39. MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B‐CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS.
40. Bladder Involvement of Diffuse Large B-cell Lymphoma Diagnosed by a Cytological Study of the Urine.
41. Early Pre-B Lymphoblastic Transformation in A Patient with Refractory Anemia.
42. Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era.
43. Phenotypic analysis of blood neutrophils in a patient with chronic idiopathic neutropenia and favorable response to G-CSF treatment.
44. 9217 DNA reparation genes in genetic and epigenetic susceptibility to Chronic Lymphocytic Leukaemia.
45. Hematopoietic stem cell transplantation in chronic lymphocytic leukemia: A report of 12 patients from a single institution
46. Harms and benefits of lymphocyte subpopulations in patients with acute stroke
47. ZAP-70 in chronic lymphocytic leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.